Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-04518600 alone or with Utomilumab in advanced cancers
NCT02315066Phase 1Completed
- Sponsor
- Pfizer
- Start
- Apr 2015
- Primary completion
- Nov 2020
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of ivuxolimab in head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma and 5 more, sponsored by Pfizer. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Apr 2015; status: completed.
02
Drugs
ivuxolimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)hepatocellular carcinoma (HCC)melanomarenal cell carcinoma (RCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02315066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02315066.